JP2020535124A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535124A5
JP2020535124A5 JP2020515000A JP2020515000A JP2020535124A5 JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5 JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
heteroaryl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020515000A
Other languages
English (en)
Japanese (ja)
Other versions
JP7402792B2 (ja
JPWO2019067503A5 (enExample
JP2020535124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052797 external-priority patent/WO2019067503A1/en
Publication of JP2020535124A publication Critical patent/JP2020535124A/ja
Publication of JP2020535124A5 publication Critical patent/JP2020535124A5/ja
Priority to JP2023142246A priority Critical patent/JP2023164918A/ja
Publication of JPWO2019067503A5 publication Critical patent/JPWO2019067503A5/ja
Application granted granted Critical
Publication of JP7402792B2 publication Critical patent/JP7402792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020515000A 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤 Active JP7402792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023142246A JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563375P 2017-09-26 2017-09-26
US62/563,375 2017-09-26
PCT/US2018/052797 WO2019067503A1 (en) 2017-09-26 2018-09-26 NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023142246A Division JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Publications (4)

Publication Number Publication Date
JP2020535124A JP2020535124A (ja) 2020-12-03
JP2020535124A5 true JP2020535124A5 (enExample) 2021-11-11
JPWO2019067503A5 JPWO2019067503A5 (enExample) 2023-09-12
JP7402792B2 JP7402792B2 (ja) 2023-12-21

Family

ID=65903565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515000A Active JP7402792B2 (ja) 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Country Status (6)

Country Link
US (2) US11465983B2 (enExample)
EP (1) EP3687537A4 (enExample)
JP (2) JP7402792B2 (enExample)
AU (1) AU2018342089B2 (enExample)
CA (1) CA3072353A1 (enExample)
WO (1) WO2019067503A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067503A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2020086595A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition
CN113395965A (zh) * 2018-12-06 2021-09-14 阿尔麦克探索有限公司 用于治疗的usp19抑制剂
CA3134564A1 (en) * 2019-05-06 2020-11-12 Lawrence Marcin Inhibiting usp19
CA3167473A1 (en) 2020-02-28 2021-09-02 Immunologik Gmbh Inhibitors of human deubiquitinases for the treatment of coronaviral infections
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053924A1 (en) 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Analgetic agent
JP4725944B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤
AU2007262670B2 (en) 2006-06-22 2012-12-20 Prana Biotechnology Limited Method of treatment of glioma brain tumour
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (ja) * 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
WO2019067503A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2020086595A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition

Similar Documents

Publication Publication Date Title
JP2020535124A5 (enExample)
JP2023164918A5 (enExample)
JP2016503799A5 (enExample)
JP2020528889A5 (enExample)
MX2024004789A (es) Esteroides neuroactivos y sus metodos de uso.
JP2017536395A5 (enExample)
JP2019529490A5 (enExample)
JP2020510091A5 (enExample)
JP2020169171A5 (enExample)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP2018150331A5 (enExample)
JP2019519598A5 (enExample)
JP2009515988A5 (enExample)
JP2017531688A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
JP2017523169A5 (enExample)
JP2017504653A5 (enExample)
JP2012526728A5 (enExample)
JP2017538773A5 (enExample)
RU2006120948A (ru) Гетероциклические ингибиторы мек и способы их применения
JP2014500265A5 (enExample)
JP2018515563A5 (enExample)
JP2007504235A5 (enExample)
JP2018535261A5 (enExample)